Private Advisor Group’s Neurocrine Biosciences NBIX Stock Holding History

Private Advisor Group’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-1,020	Closed	-$124K	–	2755
2020 Q2	$124K	Buy	+1,020	New	+$113K	﹤0.01%	1583
2019 Q4	–	Sell	-1,946	Closed	-$202K	–	1707
2019 Q3	$202K	Buy	+1,946	New	+$182K	﹤0.01%	1503
2018 Q4	–	Sell	-2,879	Closed	-$354K	–	1498
2018 Q3	$354K	Buy	+2,879	New	+$327K	0.01%	1145
2015 Q1	–	Sell	-11,238	Closed	-$251K	–	1053
2014 Q4	$251K	Buy	11,238 +1,038	+10%	+$19.7K	0.02%	783
2014 Q3	$160K	Sell	10,200 -1,025	-9%	-$15.3K	0.01%	893
2014 Q2	$167K	Buy	+11,225	New	+$158K	0.01%	823

Other funds holding NBIX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Private Advisor Group's NBIX Position: Q3 2020 in Review

Private Advisor Group sold out of Neurocrine Biosciences (NBIX) in Q3 2020, closing a stake of 1,020 shares — an estimated $124K sold.

Private Advisor Group first reported a position in NBIX in Q2 2014 and held it in 6 quarters. The position peaked at $354K in Q3 2018. 418 funds tracked by Wall St. Rank hold NBIX as of Q3 2020.

Private Advisor Group reported no remaining Neurocrine Biosciences position as of Q3 2020 after selling out during the quarter.
Private Advisor Group sold 1,020 Neurocrine Biosciences shares in Q3 2020, an estimated $124K.
Private Advisor Group first reported a position in Neurocrine Biosciences in Q2 2014 and held it in 6 quarters.
Private Advisor Group's Neurocrine Biosciences position peaked at $354K in Q3 2018.
418 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2020.

Based on Private Advisor Group's 13F filing for Q3 2020, filed 2 Nov 2020.